VEGFxPD-(L)1 Multispecifics Report
Following the release of standout data for ivonescimab and surge in recent deals between major biopharma such as Summit Therapeutics and Pfizer clinical collaboration, we have analysed the emergence of VEGFxPD-(L)1 multispecifics.
With exclusive data from Beacon, this review contains:
- Insights into the potential of VEGFxPD-(L)1 multispecifics becoming the new standard of care in lung cancer
- Analysis of the combination therapies that are being evaluated in VEGFxPD-(L)1 clinical trials
- An overview of the VEGFxPD-(L)1 licensing deals between major biopharma companies
You May Also Be Interested In…
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
